Patients must have melanoma that is metastatic and clearly progressive on prior therapy
Progressive disease during or after treatment with at least one of the agents listed above
Subjects with CNS disease must have been on a stable dose of steroids for 2 weeks prior to their biopsy and must not have progressive hydrocephalus at enrollment.
Early or confirmed evidence of progressive disease.
Patients with rapidly progressive intermediate or high grade NHL
Progressive disease in the setting of medical or surgical castration (i.e., CRPC)
Rapidly progressive disease.
Patients must have at least ONE of the following: 1) Recurrent/progressive disease at any time prior to study enrollment, 2) Refractory disease, 3) Persistent disease
Patients with progressive extracranial disease will not be excluded
Patients may have progressive systemic disease
Progressive cancer at the time of study entry
Participants who achieve either a partial response or stable disease >= 4 months must agree to undergo a tumor biopsy, if safe and feasible, at the time of progressive disease while on study drug everolimus
Are progressive.
Hyperleukocytosis (>= 50,000 blasts/uL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy
Participants with progressive systemic malignancy
Progressive disease defined by RECIST criteria =< 14 months
TREATMENT EXCLUSION: Subjects with rapidly progressive disease, defined as kinetic failure to previous chemotherapy
Patients must not have experienced confirmed progressive disease since the time of their transplant
Any episode of progressive disease during aggressive multi-drug frontline therapy.
Progressive disease and no effective therapy exists
Hyperleukocytosis (>= 50,000 blasts/uL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy
Progressive disease (AD worse) in non-risk organs after 6 weeks (Initial Course
Patients with progressive disease in risk organs
Unstable or rapidly progressive disease, including patients who require glucocorticoids for symptomatic control of brain or spinal tumors
Patients with rapidly progressive disease (PD) unresponsive to reinduction chemo, radio, or immunotherapy are ineligible.
Progressive disease following at least one first line standard therapy.
Patients must have progressive disease at study entry
At least one symptomatic and/or progressive liver lesion over a period of up to 12 months
Hyperleukocytosis (? 50,000 blasts/uL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy
Current medical need for therapy due to disease-related symptoms, lymphadenopathy, organomegaly, extranodal organ involvement, or progressive disease.
Rapidly progressive symptoms of mCRPC.
ARM I EXCLUSION CRITERIA: Any evidence of progressive systemic disease (by RECIST 1.1); those with stable systemic lesion(s) may be considered for enrollment
Has any evidence of progressive systemic disease (by RECIST 1.1); those with stable systemic lesion may be considered for enrollment
Patients with rapidly progressive intermediate or high grade NHL
Patients must have evidence of progressive disease
Progressive disease at study entry defined as 1 or more of the following 3 criteria:
Chemotherapy (chemo)-resistant (defined by stable disease [SD] or progressive disease [PD] to most recent chemo regimen)
If the diagnosis is MPN-AP/BP, must have progressive/resistant disease after treatment with a DNMT1 inhibitor therapy (azacytidine, decitabine) as determined by the treating investigator
Progressive disease (PD) as best response to first-line therapy
Evidence of progressive MM compared to pretransplant evaluation (Cohort C)
Patients may not be less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 progressive scans at least 4 weeks apart or histopathologic confirmation
Requirement for therapy of the hematological malignancy due to disease-related symptoms, lymphadenopathy, organomegaly, extranodal organ involvement, or progressive disease.
Patients with progressive disease at time of transplant
Progressive disease despite ongoing androgen deprivation or chemotherapy. Progressive disease is defined by 1 or more of the following criteria:
Subjects must have received frontline standard therapy for high-risk neuroblastoma and meet one of the following three conditions for recurrent/progressive, refractory, or persistent disease\r\n* Recurrent/progressive disease at any time prior to enrollment (regardless of overall response to frontline therapy)\r\n* Refractory disease: persistent sites of disease after achieving a best overall response of stable disease to frontline therapy after a minimum of 4 cycles of induction therapy AND patient has never had recurrent/progressive disease\r\n* Persistent disease: persistent sites of disease after achieving a best overall response of partial response to frontline therapy after a minimum of 4 cycles of induction therapy AND patient has never had recurrent/progressive disease
Within 12 weeks of chemoradiation unless the patient fulfills criteria for early progressive disease by RANO
Intermediate or high grade NHL, mantle cell NHL, and Hodgkin disease that is progressive on salvage therapy; stable disease is acceptable to move forward provided it is non-bulky
Group I: KS requiring systemic therapy (no prior therapy required) and:\r\n* Group I patients should have one or more of the following:\r\n** T1 KS, KS on skin sufficiently widespread that it is not amenable to local therapy, or KS affecting quality of life due to local symptoms or psychological distress\r\n** KS patients with an inadequate response to pomalidomide (either progressive disease or stable disease requiring additional therapy after 4 months)\r\n** KS patients with an inadequate response to liposomal doxorubicin, paclitaxel, or other systemic chemotherapy (either progressive disease or stable disease requiring additional therapy after 6 cycles)\r\n* Group I will exclude patients eligible for Group II (below); patients with a history of multicentric Castleman disease (MCD) in the absence of any active disease (as assessed by the PI) are eligible for Group I\r\n* A wash out period off treatment of 3 weeks will be required, except in the case of patients with progressive, severe disease in which delay of treatment cannot be justified (i.e. symptomatic pulmonary KS)
Patients who have progressive disease or relapse (as defined by the IWCLL criteria) at or any time before registration on this study
Less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 progressive scans at least 4 weeks apart or histopathologic confirmation
Must not have a rapidly progressive disease
Subjects with uncontrolled distantly metastatic disease per RECIST criteria (progressive disease) on imaging following chemotherapy
No evidence of progressive disease on lenalidomide
Evidence of progressive disease on lenalidomide maintenance as per IMWG criteria
Progressive disease
Less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 progressive scans at least 4 weeks apart or histopathologic confirmation
Recurrent/progressive disease at any time
First episode of progressive disease during aggressive multi-drug frontline therapy.
Progressive disease (PD)
Rapidly progressive disease that in the estimation of the treating physician would compromise ability to complete study therapy
Progressive disease at transplant work-up
Patients must not have any evidence of progressive disease at the time of study entry
Current progressive disease, as defined by RECIST v1.1
Patients without confirmed progressive and/or refractory SM using standard RECIST criteria, or those with confirmed progressive and/or refractory SM using standard RECIST criteria.
Histologically confirmed prostate cancer, currently with progressive disease
Greater than 3 months from confirmed progressive disease on Study IPI-145-07
Progressive disease at study enrollment.
Progressive disease (PD) documented by imaging or clinical findings less than or equal to 6 calendar months after cessation of previous anti-EGFR mAb treatment
Patients must have at least ONE of the following: 1) Recurrent/progressive disease at any time prior to study enrollment, 2) Refractory disease, 3) Persistent disease
Scan within 14 days prior to initiation of study vaccinations shows no evidence of progressive disease prior to study vaccination initiation based on the Response Assessment in Neuro-Oncology (RANO) criteria; participant with progressive disease after radiation therapy will not be a candidate for the vaccine despite being previously enrolled and will be removed from the study and replaced
Intermediate or high grade NHL, mantle cell NHL, and Hodgkins disease that is progressive on salvage therapy; stable disease is acceptable to move forward provided it is non-bulky
Progressive disease at the time of enrollment
No rapidly progressive disease
At screening, patients may be included if the largest lesion is > 1 cm or > 3 in number, and there is no evidence of progressive CNS disease on brain imaging at least 90 days after treatment with surgery and/or radiation therapy
At screening, patients may be included if the largest lesion is > 1 cm or > 3 in number, if the patient has underdone treatment with surgery and/or radiation therapy and there is no evidence of progressive CNS disease on brain imaging at least 90 days after treatment
Hyperleukocytosis (>= 50,000 blasts/uL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy
Patients must have progressive disease
Patients who at the discretion of the investigator are deemed to have rapidly progressive disease
Patients must have had progressive disease on, after, or refused, appropriate approved therapy for their tumor type.
Progressive disease during or after last treatment regimen.
Must have achieved at least a stable disease (SD) for at least 1 cycle of treatment to at least 1 prior anti-myeloma regimen before developing Progressive disease (PD) (relapsed)
Progressive disease within 3 months after completion of curatively intended treatment for locoregionally advanced SCCHN.
Documented progressive metastatic CRPC will be based on at least one of the following criteria:
EXCLUSION FOR TREATMENT: Rapidly progressive disease that in the estimation of the treating physician would compromise ability to complete study therapy
Radiologic evidence of progressive disease (according to [RECIST Version 1.1) either during or within 6 months after stopping their most recent systemic therapy for RCC before enrollment into this study.
Patients must have progressive disease defined as at least one of the following:
Patients must have at least stable disease (no overt progressive disease) at the time of study registration
COHORT 1 ONLY (UROTHELIAL PROGRESSIVE DISEASE)
Patients must have progressive metastatic disease; progressive will be defined as new or progressive lesions on cross-sectional imaging
Patients must have progressive metastatic disease; progressive disease will be defined as new or progressive lesions on cross-sectional imaging
Widespread progressive disease, i.e., more than three sites of progressive disease (note that more than three sites of disease are permitted provided there are no more than three sites of progressive disease)
Evidence of progressive disease within 12 months of study entry
Progressive systemic disease
MRI post radiation therapy (RT) does not show progressive disease at time of randomization
Has progressive disease (PD) within six (6) months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC
Documented progressive (clinical and/or objective) disease after the most recent systemic therapy regimen
Patients with treated, non-progressive epidural disease are eligible
Patients with treated, non-progressive epidural disease are eligible
Patients may be on other systemic chemotherapies if progressive CNS disease occurs while on these treatments; NOTE: new systemic chemotherapies should not be started unless required to treat systemic disease and should not start until at least 1 follow up imaging study has been performed
Patients must have progressive or active disease following prior therapy for their myeloma which:
Progressive disease on prior treatment
Was not removed from carfilzomib therapy for progressive disease nor experienced progressive disease within 6 months after any prior carfizolmib therapy
Progressive disease during preoperative systemic therapy
Patients must have progressive disease within the thirteen months prior to study enrollment; progressive disease is as defined in Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, which is at least a 20% increase in the sum of diameters of target lesions and the sum must also demonstrate an absolute increase of at least 5 mm; the appearance of one or more new lesions is also considered progressive disease
Require immediate treatment for progressive CTCL
Rapidly progressive disease as judged by the investigator (examples include rapidly deteriorating performance status or symptomatic lymphangitic spread)
All patients must have progressive disease for which craniotomy and tumor resection is recommended as treatment
Progressive Disease (PD) following standard chemoradiation
Patients who have had prior cranial surgery are eligible, provided that there is evidence of measurable residual or progressive lesions, and at least 2 weeks have passed since surgery; if a patient has surgical resection followed by WBRT, then there must be evidence of progressive CNS disease after the completion of WBRT
Must have evidence of progressive disease within 12 months of study entry
Patients must have completed standard radiation therapy with concurrent TMZ and must not have evidence of progressive disease on post treatment imaging
Documented fungal disease that is progressive despite treatment
I 03. Progressive disease while receiving hormonal therapy or after surgical castration.
Currently has no evidence of progressive disease, as determined by the investigator, following previous treatment with GSK2118436 (either as monotherapy or as part of a combination treatment regimen)
Patients with rapidly progressive intermediate or high grade NHL
Progressive disease despite androgen deprivation therapy as defined by rising PSA levels or progressive soft tissue or bony disease
in the opinion of the Investigator, the subject does not have progressive disease
Rapidly progressive disease.
For pigmented villo-nodular synovitis (PVNS), patients must have a histologically confirmed diagnosis of inoperable progressive or relapsing PVNS, or resectable tumor requesting mutilating surgery, as well as demonstrated progressive disease in the last 12 months.
Patients must have relapsing disease (patients with progressive disease will be excluded); in addition, patients must have had at least two relapses in the past 18 months; relapses are defined clinically or radiographically
Patients with aggressive lymphomas (such as DLBC) must not have bulky, rapidly progressive disease immediately prior to HCT
Patients must have at least ONE of the following: 1) Recurrent/progressive disease at any time prior to study enrollment, 2) Refractory disease, 3) Persistent disease
Have progressive disease at the time of transplant
No progressive disease at the time of initiation of maintenance therapy
Progressive disease after ? 1 prior chemotherapy regimen.
The patient must have a life expectancy of 3 months or more based on the judgment of the investigators; women who have rapidly progressive symptomatic disease affecting major organ systems such as the liver and lungs will be excluded
Progressive disease while receiving a BTKi therapy, or stable disease as best response after 12 months of receiving a BTKi therapy
Systemic chemotherapy less than 14 days prior; however treatment may start earlier if there is evidence of rapidly progressive disease if approved by the principal investigator
Investigational agents within 28 days of dosing; however treatment may start earlier if there is evidence of rapidly progressive disease if approved by the principal investigator
Progressive disease without any standard therapies established
Progressive disease after temozolomide and radiation therapy (in \first relapse\)
Widespread progressive disease, i.e., more than 3 sites of progressive disease (more than 3 sites of disease are permitted provided there are no more than 3 sites of progressive disease)
Confirmed progressive disease within 18 months of enrollment on study
Patients who have not had resection of recurrent or progressive disease must have measurable disease.
Patients must have received at least one prior anticancer regimen for metastatic disease unless there is no other therapy available and evidence of progressive disease on study entry. Patients with stable disease will be included if there has been failure to respond to another drug(s) within the previous 3 months
progressive disease while receiving an AI for metastatic disease
Patient must have documented progressive disease within 3 months of his/her most recent cycle of chemotherapy
Progressive disease or marked splenomegaly and/or lymphadenopathy.
Patients must have at least ONE of the following: Recurrent/progressive disease at any time prior to study enrollment - regardless of response to frontline therapy. Refractory disease: persistent sites of disease after achieving a best overall response of no response to front line therapy after a minimum of 4 cycles of induction therapy AND patient has never had recurrent/progressive disease. Persistent disease: persistent sites of disease after achieving a best overall response of partial response to frontline therapy after a minimum of 4 cycles of induction therapy AND patient has never had recurrent/progressive disease.
Patient has evidence of progressive disease while receiving iniparib.
Progressive disease within three months of completion of curatively intended treatment for locoregionally advanced or metastatic HNSCC
Refractory is defined as experiencing less than minimal response (MR) to or progressive disease (PD) within 60 days after completion of the most recent anti-MM regimen
Metastatic progressive CRPC defined as progressive disease despite surgical castration or ongoing use of gonadotropin-releasing hormone agonists with confirmed castrate levels of testosterone
Documented relapse or progressive disease on or after any regimen
For subjects who are deemed to be eligible for high-dose interleukin-2 (IL-2) and elect to receive this therapy, such subjects must have progressive disease post-IL-2 to enter this study; such subjects must also have received and have had progressive disease after therapy with one of the agents listed
Persistent or progressive cancer following the completion of the standard therapy phase of the trial will not, in and of itself, preclude receipt of immunotherapy; however, patients will not receive immunotherapy if they have an ECOG performance status of 3 or 4 or, for children =< 10 years of age, Lansky =< 50; furthermore, patients will be removed from the trial if they develop requirements for anti-neoplastic therapy (e.g. radiation therapy) for progressive disease during the trial
Patients must have had a significant response to standard frontline therapy judged as a complete response or a very good partial response (especially for irradiated sites where complete response [CR] is often impossible to ascertain); clear evidence for persistent or progressive cancer or the administration of a salvage regimen for persistent or progressive disease precludes enrollment on Cohort 2; administration of consolidation such as autologous stem cell transplant without evidence for persistent or progressive disease does not preclude enrollment
Progressive disease after medical or surgical castration,
Patients should have any of the following disease status: a. responsive or stable disease on salvage chemotherapy or radiation therapy; b. untreated, smoldering (i.e. not rapidly progressive) relapses
Progressive disease after treatment with single-agent nivolumab
Patients who show progressive disease or are not tolerating the current chemotherapy regimen
Progressive cancer (must be considered no evidence of disease or stable)
For stage IV disease, patients may be receiving no treatment or may be receiving maintenance treatment with a target agent, chemotherapy, or immunotherapy provided the most recent imaging does not demonstrate progressive disease
Progressive cancer (must be considered no evidence of disease or stable)
Evidence of progressive disease as compared to pre-HCT (persistence of disease is permitted)
Progressive malignancy
Patient must have no evidence of progressive disease on restaging imaging within 3 months of enrollment
Patient must not have evidence of progressive disease
Evidence of progressive disease at the time of study enrollment
Patients with active, progressive or advanced disease based on diagnosis
For cohort 2 only: progressive disease (PD) on lenvatinib per RECIST 1.1 =< 30 days prior to registration, as confirmed by the site study PI
Progressive disease manifest (within 6 weeks of screening) by either
Patients must have currently progressive metastatic disease according to RECIST v1.1\n             criteria, AND
Stable disease (duration of stable disease must be less than or equal to 6 months) or progressive disease as best response to most recent chemotherapy containing regimen
Progressive Disease (PD) during prior aromatase inhibitor (AI) therapy.
Progressive disease post-surgical castration or during androgen suppression therapy (pre-secondary hormone CRPC) OR
